Protocol Ledger

NCT07303803 · Phase II · RECRUITING

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

Interventional Phase II clinical trial protocol NCT07303803 sponsored by Shanghai Jiao Tong University School of Medicine in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-01 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07303803
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07303803
Protocol FieldVerified Registry Value
NCT IdentifierNCT07303803
Consolidated Lead SponsorShanghai Jiao Tong University School of Medicine
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2026-01-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07303803
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital Of Fujian Medical UniversityFuzhou, ChinaOpen Hospital Dossier ->
Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI